Our Value Proposition
Helping to Accelerate the Availability of Safe and Effective Medicines for Patients Who Need Them.
The availability of transformative technology provides an opportunity to disrupt the current approach to regulatory submission creation and review. Current methods for data exchange and communication between each biopharmaceutical company and global health authorities have not kept pace with advancements in information technology.
A transformation is needed from a static transactional exchange between each biopharmaceutical company and regulators to a dynamic approach capable of exploiting the full range of data sources and technology tools.
Accumulus aims to provide a global collaboration platform to improve interactions and exchange real-time data globally to accelerate medicines to patients, reducing the drug lag around the world. Accumulus Synergy technology solutions will enable greater efficiency of submission and review without altering high standards for approval.
Cost to bring a pharmaceutical product to market in 20211
$2B
an increase of
$710M
from 2013
A focus on overcoming unmet needs
associated with drug lag1
“Filing a New Drug Application may have shifted from driving a truckload of paper to the relevant regulatory authority, to FedEx-ing a CD-ROM, to uploading a set of PDFs through the Electronic Submissions Gateway, but the underlying processes remain little changed. It’s long past time to play catchup —it’s time for a moon shot.”
– Francisco Nogueira, Chief Executive Officer, at Accumulus Synergy
Reference:
1. Nurturing growth: measuring the return from pharmaceutical innovation 2021. Deloitte. Available at: https://www2.deloitte.com/uk/en/pages/life-sciences-and-healthcare/articles/measuring-return-from-pharmaceutical-innovation.html. Accessed February 9, 2022.